Lipella Pharmaceuticals (LIPO) Announces U.S. Patent Issuance for Diagnostic Technology

Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced the issuance of U.S. Patent No. 12,326,492, titled “Systems and Methods of Detecting Interstitial Cystitis.” The patent was issued by the United States Patent and Trademark Office on June 10, 2025, and provides protection through at least 2045, subject to potential extensions.

The patent covers a method, using magnetic resonance imaging (MRI), to detect lesions (or permeability defects) in body cavities. "This method can potentially provide enhanced outcome assessments to our development programs; especially mucosal disorders, including our existing programs: LP-310 for oral lichen planus, LP-10 for hemorrhagic cystitis and LP-50 for bladder cancer." said Dr. Michael Chancellor, Chief Medical Officer.

“This patent strengthens Lipella’s strategic position in drug delivery,” said Jonathan Kaufman, Chief Executive Officer. "The ability to non-invasively monitor the progression (or regression) of body cavity lesions, using a novel MRI contrast agent, will not only enhance our existing clinical development efforts, but can itself become a clinically-relevant early detection tool.”

You May Also Be Interested In

• CoVolt Power files for proposed IPO
• Curvature Securities terminates ATM sales pact with Planet Green
• Solowin Holdings marks 10 years, expands into stablecoins and AI